9 studies found for:    11807147 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Unknown  The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory Central Nervous System (CNS) Lymphoma
Condition: B-Cell Lymphoma Originating in the CNS
Intervention: Drug: Temozolomide
2 Withdrawn MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma
Conditions: Lymphoma, Diffuse Large-Cell B-cell;   Diffuse, Large B-cell Lymphoma;   Lymphoma, Diffuse Large-Cell;   Large-Cell Lymphoma, Diffuse
Interventions: Drug: MLN4924;   Drug: Etoposide;   Drug: Prednisone;   Drug: Vincristine;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Rituximab;   Drug: Filgrastim
3 Recruiting Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia
Condition: Precursor Cell Lymphoblastic Leukemia-Lymphoma
Intervention: Drug: Rituximab+mVPDL
4 Terminated R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-Cell Lymphoma
Condition: Lymphoma, Large-Cell, Diffuse
Interventions: Drug: CHOP plus rituximab;   Drug: ACVBP plus rituximab
5 Completed LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)
Conditions: HIV Infections;   Diffuse Large B Cell Lymphoma
Interventions: Drug: R-CHOP;   Drug: Highly active antiretroviral therapy;   Drug: Central nervous system (CNS) prophylaxis;   Drug: Prophylaxis of opportunistic infections and support treatment
6 Completed Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy With Diffuse Large Cell Lymphoma
Conditions: Lymphoma;   Diffuse Large Cell
Intervention: Procedure: Blood draw
7 Unknown  Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma
Condition: B Cell Lymphoma
Intervention: Drug: Rituximab -CHOP plus Velcade
8 Unknown  Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma
Condition: Diffuse Large Cell Lymphoma
Intervention: Drug: Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)
9 Completed R-ICE (ICE Plus Rituximab) Versus R-DHAP (DHAP Plus Rituximab) in Patients Aged 18-65 With Relapse Diffuse Large B-Cell Lymphoma
Condition: Lymphoma, Large-Cell, Diffuse
Interventions: Drug: DHAP plus rituximab;   Drug: ICE plus rituximab

Indicates status has not been verified in more than two years